However, it is not known whether the anti-CD4 mAb treatment expands a part of the highly activated tumor-specific CTL clones or mobilizes a wide variety of tumor-reactive CD8+ T cell clones into the antitumor CTL response. This evidence concerns the gene CD8A and neoplasm.